Solventum Corp

Company facts

Industry

Surgical & Medical Instruments & Apparatus

Headquarters

Eagan, Minnesota

Most recent report

10-Q, filed Aug 5, 2026

Incorporated

Delaware

Filings on record

261 filings

On EDGAR

CIK 1964738

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 3 of 13 sections worth reading, with 0 positive, 5 notable, and 2 negative flags.

• Financial Statements (Item 1)

  Core financials with big litigation charge ($204M) and cash burn.
  Notable

  • Tariff refunds of $120M accepted; $100M pre-tax benefit recognized.
  Negative

  • $204M litigation charge in Q2 2026; accrual jumped from $31M to $235M.

• Management's Discussion (Item 2)

  Core MD&A with company-specific results, cash burn, IEEPA refund, ERP distortion.
  Notable

  • Announced intent to separate Health Information Systems business on August 5, 2026.
  • Q2 organic growth 9.5%, but $125M is from ERP pull-forward that will reverse in Q3.
  • Repurchased $288M in Q2 and $355M in H1 2026 under the $1B authorization.
  Negative

  • Cash balance dropped to $403M at June 30, 2026 from $878M at Dec 31, 2025.

• Risk Factors (Item 1A)

  Contains a new, company-specific risk factor on strategic review.
  Notable

  • Company reviewing strategic alternatives for health information systems business; outcome uncertain.

What changed: Jun 2026 vs. Mar 2026

About 14% of SOLV's Jun 2026 10-Q is new information. 45 paragraphs were added, 127 changed, and 14 removed. Below are the most important lines SECSift identified.

• Item 1 59
• Item 2 57
• Item 6 4
• Item 1A 3
• Item 4 2
• Item 5 1